Danish National Genome Center Selects QIAGEN for Variant Interpretation in Oncology Genome Sequencing
13 June 2023
The QCI Interpret solution was chosen by the Danish National Genome Center to provide interpretation of oncology results generated from whole-genome sequencing (WGS) data. The initiative is part of a larger personalized medicine strategy that aims to provide WGS as the standard-of-care for relevant patient groups throughout Denmark.
Denmark is one of the first countries in the world to implement WGS as standard-of-care for oncology at this scale, and to adopt QCI Interpret to support the national initiative. The country aims to gain sufficient genetic data to truly utilize the power of genomics in personalized medicine to improve outcomes for patients through better cancer diagnosis and treatment decisions.
“We are pleased to partner with the Danish National Genome Center in this landmark program to provide nationwide access to the power of sequencing for cancer patients in Denmark,” said Jonathan Sheldon, Executive Vice President and Head of QIAGEN Digital Insights. “Denmark is taking a visionary approach to aggregating genomic data and combining it with clinical information on cancer patients to develop enhanced population-specific knowledge and reference sets for the country’s residents. This will serve as a foundation for effective precision medicine capabilities for years to come. This partnership also demonstrates QIAGEN’s ability to support national precision medicine programs in terms of infrastructure and technology support. Together we are determined to advance the power of molecular insights from bench to bedside.”
Denmark has strict requirements for data privacy and security, requiring all data to be processed and stored within the country and only accessed from within the National Genome Center infrastructure. QCI Interpret, allows authorized staff from labs across the country to interpret whole genome sequencing data consistently and efficiently while meeting data privacy and security requirements.
“QCI Interpret delivers evidence-based variant interpretation and reporting, adheres to the highest level of data security and privacy, and allows for flexibility at distributed testing sites throughout the country that use different next-generation sequencing instruments. The platform is an agnostic solution that can be easily integrated with any pipeline to enable users to go from variant calls to final report within minutes,” said Dan Richards, Vice President of Clinical Product Management at QIAGEN Digital Insights.
Test analysis and interpretation are key barriers to implementing WGS at-scale. The Danish National Genome Center selected QCI Interpret to streamline and accelerate the interpretation, and reporting process. Connected to the QIAGEN Knowledge Base, a comprehensive, manually curated resource that is updated weekly, QCI Interpret dynamically computes pathogenicity and actionability based on professional guidelines for every variant in over 31,000 cancer types. In addition, users have access to over 460,000 preformulated, oncologist-reviewed variant impact summaries to build custom, patient-specific reports with the latest evidence and prognostic information, as well as biomarker-directed therapies and clinical trials.
